These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 24945646)

  • 1. Cutaneous thrombogenic vasculopathy associated with bevacizumab therapy.
    Kiuru M; Schwartz M; Magro C
    Dermatol Online J; 2014 Jun; 20(6):. PubMed ID: 24945646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ulcerations within striae distensae associated with bevacizumab therapy.
    Farber SA; Samimi S; Rosenbach M
    J Am Acad Dermatol; 2015 Jan; 72(1):e33-5. PubMed ID: 25497948
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute and severe acne in a patient treated with bevacizumab.
    Molina-Ruiz AM; Domine M; Requena L
    Int J Dermatol; 2013 Apr; 52(4):486-90. PubMed ID: 23432695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
    Lomax AJ; Hill PA; Ashley DM
    J Oncol Pharm Pract; 2013 Dec; 19(4):365-8. PubMed ID: 23235917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
    August DA; Serrano D; Poplin E
    J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH; Shen YL; Keegan P; Pazdur R
    Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab: more fatal adverse effects.
    Prescrire Int; 2012 Nov; 21(132):266-7. PubMed ID: 23210257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.
    Saif MW; Longo WL; Israel G
    Clin Colorectal Cancer; 2008 Mar; 7(2):144-8. PubMed ID: 18501075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
    Frangié C; Lefaucheur C; Medioni J; Jacquot C; Hill GS; Nochy D
    Lancet Oncol; 2007 Feb; 8(2):177-8. PubMed ID: 17267332
    [No Abstract]   [Full Text] [Related]  

  • 11. Osteonecrosis of the mandible associated with bevacizumab therapy.
    Santos-Silva AR; Belizário Rosa GA; Castro Júnior Gd; Dias RB; Prado Ribeiro AC; Brandão TB
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Jun; 115(6):e32-6. PubMed ID: 23567260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
    Narita Y
    Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
    Sandler AB; Johnson DH; Herbst RS
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapy.
    Cottu PH; Fourchotte V; Vincent-Salomon A; Kriegel I; Fromantin I
    J Wound Care; 2011 Sep; 20(9):403-4, 406, 408 passim. PubMed ID: 22068139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
    Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
    J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ulceration of abdominal striae distensae (stretch marks) in a cancer patient.
    Dosal J; Handler MZ; Ricotti CA; Vega J; Tosti A; Kerdel FA
    Arch Dermatol; 2012 Mar; 148(3):385-90. PubMed ID: 22431783
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Papulopustular eruption after intravitreal bevacizumab (Avastin).
    Amselem L; Diaz-Llopis M; Garcia-Delpech S; Montero J; Palomares P; Cervera E
    Acta Ophthalmol; 2009 Feb; 87(1):110-1. PubMed ID: 18577190
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous lupus erythematosus in a patient undergoing intravitreal bevacizumab injections: case report and review of the literature.
    Cleaver N; Ramirez J; Gildenberg S
    J Drugs Dermatol; 2013 Sep; 12(9):1052-5. PubMed ID: 24002156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.